Tracee L. McMiller
Johns Hopkins University · 89 works · 19,493 citations · h-index 16
Top works
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
- Mechanisms regulating PD-L1 expression on tumor and immune cells
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Abstract 446: Differential expression of immuno-regulatory genes associated with PD-L1 display: Implications for clinical blockade of the PD-1/PD-L1 pathway in melanoma.
- The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
- Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma
- Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy
- Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
- Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
- Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: implications for immunotherapy
- Molecular characterization of HLH-17, a C. elegans bHLH protein required for normal larval development
- Identifying Novel Helix–Loop–Helix Genes in Caenorhabditis elegans through a Classroom Demonstration of Functional Genomics
- Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
- Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas
- Melanoma and immunotherapy bridge 2015
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
- Structure-Based Design of Altered MHC Class II–Restricted Peptide Ligands with Heterogeneous Immunogenicity